APA (7th ed.) Citation

Ozcan, L., Kasikara, C., Yurdagul, A., Kuriakose, G., Hubbard, B., Serrano-Wu, M. H., & Tabas, I. (2021). Allosteric MAPKAPK2 inhibitors improve plaque stability in advanced atherosclerosis. PLoS ONE, 16(5), 1. https://doi.org/10.1371/journal.pone.0246600

Chicago Style (17th ed.) Citation

Ozcan, Lale, Canan Kasikara, Arif Yurdagul, George Kuriakose, Brian Hubbard, Michael H. Serrano-Wu, and Ira Tabas. "Allosteric MAPKAPK2 Inhibitors Improve Plaque Stability in Advanced Atherosclerosis." PLoS ONE 16, no. 5 (2021): 1. https://doi.org/10.1371/journal.pone.0246600.

MLA (9th ed.) Citation

Ozcan, Lale, et al. "Allosteric MAPKAPK2 Inhibitors Improve Plaque Stability in Advanced Atherosclerosis." PLoS ONE, vol. 16, no. 5, 2021, p. 1, https://doi.org/10.1371/journal.pone.0246600.